Holen Sie sich die Stockscreener-App
24.61
0.26%
0.0704
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt PFE?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$24.54
Offen:
$24.5
24-Stunden-Volumen:
12.66M
Relative Volume:
0.32
Marktkapitalisierung:
$139.18B
Einnahmen:
$63.63B
Nettoeinkommen (Verlust:
$8.03B
KGV:
17.45
EPS:
1.41
Netto-Cashflow:
$9.84B
1W Leistung:
-2.40%
1M Leistung:
-6.91%
6M Leistung:
-14.00%
1J Leistung:
-10.69%
1-Tages-Spanne:
$24.31
$24.72
1-Wochen-Bereich:
$24.31
$25.43
52-Wochen-Spanne:
$24.31
$31.54
Pfizer Inc Stock (PFE) Company Profile
Firmenname
Pfizer Inc
Sektor
Telefon
(212) 733-2323
Adresse
66 HUDSON BOULEVARD EAST, NEW YORK, NY
Vergleichen Sie PFE mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PFE
Pfizer Inc
|
24.61 | 139.18B | 63.63B | 8.03B | 9.84B | 1.41 |
|
LLY
Lilly Eli Co
|
804.96 | 719.11B | 45.04B | 10.59B | 414.30M | 11.71 |
|
ABBV
Abbvie Inc
|
204.65 | 359.93B | 56.33B | 4.28B | 17.83B | 2.40 |
|
JNJ
Johnson Johnson
|
154.96 | 344.63B | 88.82B | 14.07B | 18.06B | 5.79 |
|
NVO
Novo Nordisk Adr
|
67.75 | 301.99B | 42.09B | 14.65B | 10.11B | 3.2833 |
|
NVS
Novartis Ag Adr
|
109.44 | 216.49B | 51.72B | 11.94B | 13.81B | 5.88 |
Pfizer Inc Stock (PFE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-10 | Fortgesetzt | BofA Securities | Neutral |
| 2024-11-15 | Eingeleitet | Wolfe Research | Underperform |
| 2024-10-25 | Fortgesetzt | Citigroup | Neutral |
| 2024-10-17 | Eingeleitet | Bernstein | Mkt Perform |
| 2024-08-07 | Hochstufung | Daiwa Securities | Neutral → Outperform |
| 2024-03-22 | Herabstufung | Argus | Buy → Hold |
| 2024-02-23 | Eingeleitet | Guggenheim | Buy |
| 2024-01-04 | Herabstufung | TD Cowen | Outperform → Market Perform |
| 2023-10-20 | Fortgesetzt | UBS | Neutral |
| 2023-10-16 | Hochstufung | Jefferies | Hold → Buy |
| 2023-07-17 | Bestätigt | JP Morgan | Neutral |
| 2023-07-14 | Eingeleitet | HSBC Securities | Buy |
| 2023-06-29 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2023-05-11 | Herabstufung | Daiwa Securities | Outperform → Neutral |
| 2023-03-06 | Eingeleitet | Jefferies | Hold |
| 2023-02-07 | Hochstufung | Daiwa Securities | Neutral → Outperform |
| 2023-01-26 | Herabstufung | UBS | Buy → Neutral |
| 2023-01-17 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2023-01-04 | Herabstufung | BofA Securities | Buy → Neutral |
| 2022-12-13 | Hochstufung | Goldman | Neutral → Buy |
| 2022-11-18 | Eingeleitet | Credit Suisse | Outperform |
| 2022-05-23 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2022-04-06 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2022-01-05 | Hochstufung | BofA Securities | Neutral → Buy |
| 2022-01-03 | Bestätigt | Bernstein | Mkt Perform |
| 2021-12-20 | Bestätigt | Cowen | Outperform |
| 2021-12-17 | Eingeleitet | Goldman | Neutral |
| 2021-12-13 | Hochstufung | UBS | Neutral → Buy |
| 2021-12-09 | Eingeleitet | Wells Fargo | Overweight |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Outperform |
| 2021-07-27 | Fortgesetzt | Truist | Buy |
| 2021-05-06 | Herabstufung | Mizuho | Buy → Neutral |
| 2021-04-07 | Fortgesetzt | RBC Capital Mkts | Sector Perform |
| 2021-02-04 | Hochstufung | DZ Bank | Hold → Buy |
| 2020-12-16 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-11-19 | Fortgesetzt | Goldman | Neutral |
| 2020-11-10 | Fortgesetzt | Bernstein | Mkt Perform |
| 2020-10-12 | Herabstufung | Atlantic Equities | Overweight → Neutral |
| 2020-09-29 | Eingeleitet | Berenberg | Hold |
| 2020-06-16 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2020-02-27 | Eingeleitet | Barclays | Equal Weight |
| 2020-02-27 | Hochstufung | Standpoint Research | Hold → Buy |
| 2020-02-06 | Eingeleitet | Mizuho | Buy |
| 2020-01-07 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2019-10-17 | Fortgesetzt | BofA/Merrill | Neutral |
| 2019-07-30 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2019-07-30 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2019-06-04 | Fortgesetzt | Morgan Stanley | Overweight |
| 2019-02-20 | Fortgesetzt | Citigroup | Neutral |
| 2019-01-31 | Hochstufung | Argus | Hold → Buy |
| 2019-01-31 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2019-01-23 | Herabstufung | UBS | Buy → Neutral |
| 2018-12-11 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2018-11-01 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
Alle ansehen
Pfizer Inc Aktie (PFE) Neueste Nachrichten
Pfizer stock hits 52-week low at $24.42 amid market shifts - Investing.com Australia
Proxy adviser ISS recommends Pfizer shareholders reject executive compensation proposal - MarketScreener
Proxy adviser ISS recommends Pfizer shareholders to vote against CEO compensation - Reuters
Antibacterial Drugs Market Is Booming So Rapidly 2025-2032 - openPR.com
PFE Secures EU Nod for Expanded Use of RSV Vaccine Abrysvo - TradingView
3 Value Stocks Worth Buying in Current Market Conditions - Investing.com
Pfizer Crosses Above 7% Yield Territory - Forbes
Pfizer wins label expansion for RSV shot in EU (PFE:NYSE) - Seeking Alpha
Pfizer, Merck Lose Appeal To Patent Cancer Drug Dosage - Law360
Pfizer (NYSE:PFE) Expands RSV Vaccine Use In Europe Amid 3% Share Price Dip - simplywall.st
Potential Stock Woe Ahead as Pfizer (PFE) Riles Donald Trump - TipRanks
Will Pfizer (PFE) Beat Estimates Again in Its Next Earnings Report? - Yahoo Finance
Global markets live: Tesla, Chevron, Pfizer, Michelin, Toyota… - MarketScreener
Injectable Drugs Market to Witness Massive Growth by 2032 | - openPR.com
Is Pfizer Inc. (PFE) the Most Undervalued Healthcare Stock to Buy According to Analysts? - Yahoo Finance
Flagship Pioneering Agreement With Pioneering Medicines & Pfizer To Discover Potential Novel, Selective Inhibitors For Autoimmune Disease - MarketScreener
Former Pfizer CSO Mikael Dolsten on writing his next chapter, embracing AI and asking the ‘big questions’ - PharmaVoice
Pfizer: extension of indication for RSV vaccine - MarketScreener
Major Breakthrough: Pfizer Teams With Flagship to Develop AI-Driven Autoimmune Treatments - Stock Titan
Pfizer’s RSV vaccine wins expanded approval in EU, gaining edge over GSK - Yahoo Finance
Pfizer Says European Commission Approves Abrysvo RSV Vaccine for Adults - MarketScreener
European Commission approves Pfizer's RSV vaccine for adults at increased risk of disease - Reuters
European Commission Approves Pfizer’s RSV Vaccine ABRYSVO® to Help Protect Adults Aged 18-59 Against RSV Lower Respiratory Tract Disease - Yahoo Finance
Pfizer COVID-19 Bombshell Puts 2020 Election Into Context - The Daily Signal
Inflammatory Myositis Market on Track for Major Expansion by 2034, According to DelveInsight | CSL Behring, Argenx, Priovant Therapeutics/Roivant, Alexion Pharma, Pfizer, Horizon Therapeutics - Barchart.com
Is Trending Stock Pfizer Inc. (PFE) a Buy Now? - Yahoo Finance
Pfizer: Looks Better Than Most, But I Can't Eat Relative Returns - Seeking Alpha
Top 12 Pharma Companies: Pfizer Tops The Leaderboard Again - insights.citeline.com
Allianz SE Makes New $19.48 Million Investment in Pfizer Inc. (NYSE:PFE) - MarketBeat
Pfizer Inc. (PFE): Among Blue Chip Stocks to Invest in at 52-Week Lows - Insider Monkey
Pfizer and other pandemic favorites in focus as FDA’s top vaccine regulator resigns - Seeking Alpha
What Does the Market Think About Pfizer? - Benzinga
Pfizer: Shares Stabilize At $25 As Institutions Begin To Load Up (Rating Upgrade) - Seeking Alpha
Minoxidil Market Set to Witness Significant Growth by 2025-2032 - openPR
Pfizer leader who launched Covid vaccine gives small pharma a try - The Business Journals
Senator Slams Pfizer (PFE) for “Biggest Tax-Dodging Scheme in Pharma History” - markets.businessinsider.com
UC San Diego Moores Cancer Center Receives $1M Donation from Pfizer for Early Cancer Detection | Newswise - Newswise
Pfizer: Value Play Or Past Its Prime? - Barchart
Pfizer: Value Play or Past Its Prime? - The Globe and Mail
Pfizer Tops Pharma Tax Avoidance, Senate Dems Say - Law360
US prosecutors probe tip about timing of Pfizer's COVID vaccine, WSJ reports - Reuters
Pfizer ran what could be the largest tax dodging scheme among Big Pharma: Senator - Seeking Alpha
Sector Update: Health Care - Marketscreener.com
Pfizer's Bold Tax Maneuver Sparks Controversy - Finimize
Is Pfizer Stock A Sell With A Looming First-Quarter Slowdown? - Investor's Business Daily
Pfizer Avoided Billions in Taxes on Sales, Democrats Say (2) - Bloomberg Tax
Living with Colon Cancer: A Pfizer Colleague’s Story - Pfizer
May 9th Options Now Available For Pfizer (PFE) - Nasdaq
GSK accuses Pfizer of delaying Covid vaccine result until after US election - Yahoo
Is Pfizer Inc.'s (NYSE:PFE) Recent Price Movement Underpinned By Its Weak Fundamentals? - Yahoo Finance
Why Pfizer Is My Largest Healthcare Position - MSN
Finanzdaten der Pfizer Inc-Aktie (PFE)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.08%
0.81%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):